Señales en vivo de KLAR.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:29):

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy...

Stats
Volumen de hoy	245 729
Volumen promedio	323 610
Capitalización de mercado	35.04M
EPS	SEK-0.101 ( 2023-11-24 )
Próxima fecha de ganancias	( SEK0 ) 2024-05-10
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.670
ATR14	SEK0.00900 (2.74%)

Volumen Correlación

Largo: -0.02 (neutral)

Corto: -0.55 (weak negative)

Signal:(46.363) Neutral

Klaria Pharma Holding AB Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Klaria Pharma Holding AB Correlación - Moneda/Commodity

-0.71
( moderate negative )

-0.52
( weak negative )

0.00
( neutral )

-0.70
( moderate negative )

0.00
( neutral )

-0.21
( neutral )

Klaria Pharma Holding AB Finanzas

Annual	2023
Ingresos:	SEK0
Beneficio Bruto:	SEK-9 000.00 (0.00 %)
EPS:	SEK-0.360

FY	2023
Ingresos:	SEK0
Beneficio Bruto:	SEK-9 000.00 (0.00 %)
EPS:	SEK-0.360

FY	2022
Ingresos:	SEK5.87M
Beneficio Bruto:	SEK5.87M (100.00 %)
EPS:	SEK-1.100

FY	2021
Ingresos:	SEK0.00
Beneficio Bruto:	SEK0.00 (0.00 %)
EPS:	SEK-1.030

Financial Reports:

No articles found.

Klaria Pharma Holding AB

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.